Lyell Wealth Management LP Purchases 735 Shares of iShares Biotechnology ETF (NASDAQ:IBB)

Lyell Wealth Management LP boosted its holdings in iShares Biotechnology ETF (NASDAQ:IBB) by 3.4% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 22,274 shares of the financial services provider’s stock after buying an additional 735 shares during the quarter. Lyell Wealth Management LP’s holdings in iShares Biotechnology ETF were worth $3,243,000 at the end of the most recent reporting period.

Several other hedge funds have also added to or reduced their stakes in IBB. Future Financial Wealth Managment LLC bought a new position in shares of iShares Biotechnology ETF during the first quarter valued at $27,000. Bbjs Financial Advisors LLC bought a new position in iShares Biotechnology ETF during the 2nd quarter worth $31,000. Chris Bulman Inc acquired a new position in iShares Biotechnology ETF during the 2nd quarter worth about $64,000. Eastern Bank acquired a new position in iShares Biotechnology ETF during the 3rd quarter worth about $65,000. Finally, BNP Paribas bought a new stake in shares of iShares Biotechnology ETF in the 1st quarter valued at about $69,000. 62.45% of the stock is currently owned by institutional investors and hedge funds.

iShares Biotechnology ETF Price Performance

Shares of IBB stock opened at $141.51 on Friday. iShares Biotechnology ETF has a 1-year low of $111.83 and a 1-year high of $150.57. The stock has a 50-day moving average of $145.56 and a 200-day moving average of $139.99.

iShares Biotechnology ETF Announces Dividend

The company also recently announced a dividend, which was paid on Monday, September 30th. Shareholders of record on Wednesday, September 25th were given a dividend of $0.2005 per share. The ex-dividend date of this dividend was Wednesday, September 25th.

iShares Biotechnology ETF Profile

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.